期刊
PHARMACEUTICS
卷 15, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics15020459
关键词
atherosclerotic cardiovascular disease; cardiovascular prevention; hyperlipidemia; hypertriglyceridemia; lipoprotein (a)
This article provides an update on the use of monoclonal antibodies, gene silencing therapies, and gene editing techniques for the management of hyperlipidemia. It reviews the cutting-edge pharmaceuticals targeting LDL cholesterol, PCSK9, lipoprotein (a), angiopoietin-like 3, and apolipoprotein C3. The available and upcoming biotechnological lipid therapies are discussed for clinicians managing patients with familial hyperlipidemia, statin intolerance, hypertriglyceridemia, or elevated lipoprotein (a) levels.
Hyperlipidemia is a significant risk factor for atherosclerotic cardiovascular disease. Undertreatment of elevated lipids persists despite existing therapies. Here, we provide an update on monoclonal antibodies, gene silencing therapies, and gene editing techniques for the management of hyperlipidemia. The current era of cutting-edge pharmaceuticals targeting low density lipoprotein cholesterol, PCSK9, lipoprotein (a), angiopoietin-like 3, and apolipoprotein C3 are reviewed. We outline what is known, studies in progress, and futuristic goals. This review of available and upcoming biotechnological lipid therapies is presented for clinicians managing patients with familial hyperlipidemia, statin intolerance, hypertriglyceridemia, or elevated lipoprotein (a) levels.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据